NCT06340230View on ClinicalTrials.gov

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2031

Conditions
HR Positive/HER2 Low Breast Cancer
Interventions
DRUG

SHR-A1811 Injection + Adebrelimab Injection

Drug: SHR-A1811 Injection Drug: Adebrelimab Injection

DRUG

SHR-A1811 Injection + Adebrelimab Injection

Drug: SHR-A1811 Injection Drug: Adebrelimab Injection

DRUG

SHR-A1811 Injection

Drug: SHR-A1811 Injection

Trial Locations (1)

110004

RECRUITING

Shengjing Hospital affiliated to China Medical University, Shenyang

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Shengjing Hospital

OTHER